Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "sandoz inc"

Amgen And Sandoz Do Biosimilar Patent Dance Over Neulasta

Amgen Inc. has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA) , asserting that a biosimilar application filed by Sandoz Inc. seeking approval of a biosimilar version of Neulasta® infringes two of its patents. National Law Review, 1 week ago

Sandoz Canada Inc. launches PrTOBRAMYCIN INHALATION SOLUTION, a generic version of PrTOBI indicated for pulmonary infections in cystic fibrosis patients

(GLOBE NEWSWIRE) Sandoz Canada Inc. announced the launch of PrTOBRAMYCIN INHALATION SOLUTION, an authorized generic version of PrTOBI*, currently marketed by Novartis Pharmaceuticals Canada Inc. PrTOBRAMYCIN INHALATION SOLUTION, a respiratory ...
 Pharmacy Choice1 month ago NOVARTIS : Sandoz Canada Inc. launches PrTOBRAMYCIN INHALATION SOLUTION, a generic version of PrTOBI indicated for pulmonary infections in cystic fibrosis...  4 Traders1 month ago
Powder Bulk Solids

Pfizer To Acquire Anacor

PRESS RELEASE Pfizer Inc. (NYSE:PFE) and Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total ...
 Pharmacy Times1 week ago Anacor Pharmaceuticals Stock Rockets Following News Of Pfizer Purchase  Investing.com1 week ago Pfizer Enters Merger Agreement with Anacor  Powder Bulk Solids1 week ago Pfizer to buy pharmaceutical company in $5.2B deal  AOL.com1 week ago
[x]  

Should AbbVie Inc (ABBV) Feel Threatened By Coherus Humira Patent Challenge?

The US Patent Office shows its positive response to a patent challenge for Humira AbbVie Inc ( NYSE:ABBV ) plunged around 4.5% today after the US Patent and Trademark Office agreed to consider a patent challenge filed by Coherus BioSciences to ...
 Bidness Etc1 week ago
Nasdaq

Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio

Pfizer Inc. PFE announced that it will be acquiring biopharmaceutical company, Anacor Pharmaceuticals, Inc. ANAC , for $99.25 per share or a total of about $5.2 billion (assuming the conversion of Anacor's outstanding convertible notes). Anacor's ...
 Zacks.com1 week ago Pfizer to buy California-based biopharma company, Anacor for $5.2 billion  PharmaBiz1 week ago
[x]  

Anacor Pharmaceuticals' (ANAC) CEO Paul Bernson on Q1 2016 Results - Earnings Call Transcript

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC ) Q1 2016 Earnings Conference Call May 10, 2016 08:00 AM ET Executives DeDe Sheel - Head of Investor Relations Paul Berns - Chairman and CEO Graeme Bell - CFO Vince Ippolito - Chief ...
 Seeking Alpha2 weeks ago Antares Pharma's (ATRS) CEO Bob Apple on Q1 2016 Results - Earnings Call Transcript  Seeking Alpha2 weeks ago Lannett (LCI) Arthur P. Bedrosian on Q3 2016 Results - Earnings Call Transcript  Seeking Alpha3 weeks ago Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q1 2016 Results - Earnings Call Transcript  Seeking Alpha3 weeks ago

Merck May Need More Than Just Bolt-On Acquisitions

Shares of Merck & Co. Inc. (NYSE: MRK ) have pulled back about 5.75% from the April high, along with the S&P 500 Healthcare sector, down 2.38%, on concerns about interest rate decisions from the Fed, and the Senate Special Committee on Aging's third ...
 Seeking Alpha2 weeks ago
Bidness Etc

Teva, Mylan, Endo: Why Generic Drug Prices Are Dropping

The stocks of companies that manufacture generic drugs are in trouble as the market faces pricing pressures brought on by increased consolidation, and an uptick in the number of regulatory approvals. According to data from Symphony Health, median ...
 Bidness Etc2 weeks ago
TeleTrader.com

Apricus Biosciences Provides Corporate Update and First Quarter Financial Results

(GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2016 and provided a corporate update on ...
 Benzinga.com2 weeks ago CORRECTING and REPLACING Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros and Erectile Dysfunction Population  Pharmacy Choice3 weeks ago CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population  Financial Buzz3 weeks ago CORRECTING and REPLACING — Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population  PM 3603 weeks ago
[x]  

Aequus Pharmaceuticals Inc. (AQSZF: OTCQB) | Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN(TM) in Canada

) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that it has initiated commercial activities for PR Vistitan (bimatoprost 0.03%, ophthalmic solution) in the Canadian market, which is a ...
 OTC Markets3 weeks ago Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN(TM) in Canada  Sys-Con Italia3 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less